17554 Holly Well Ave., Tampa, FL 33598
Sept. 9, 2026 Weight Watchers announced today that it has appointed Stephen Bye as its President and CEO and a member of the company’s Board of Directors. “Bye’s appointment will become effective this fall. He most recently served as President and CEO of Ookla, a global connectivity intelligence company whose industry leading brands include Speedtest, […]
Weight Watchers Hires New CEO Read More »
August 5, 2026 WW reported its Q2 results today. Management said: “We view 2026 as a year of focused transition for Weight Watchers, and our Q2 results reflect that work taking hold across the business,” said Jon Volkmann, Chief Operations Officer and member of the Company’s Interim Office of the Chief Executive. “Core+, our high-value
Weight Watchers Reports Q2 Results Read More »
May 6, 2026 Medifast reports its first quarter 2026 results. According to management: “We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership advancement, and high field engagement. These are metrics that have historically been
Medifast Reports Q1 2026 Results Read More »
April 2, 2026 On April 1, 2026, the FDA approved Foundayo (orforglipron), a new once-daily oral GLP-1 weight loss pill developed by Eli Lilly for adults with obesity or overweight and at least one weight-related condition. Unlike other options, Foundayo does not require fasting or specific timing. It mimics a natural hormone to regulate appetite and,
New Eli Lilly Weight Loss Pill Approved – Foundayo Read More »
March 15, 2026 Medifast is an MLM (multilevel marketer) that sells meal replacements and diet foods, via health coaches. Their sales declined by 36% in 2025, to $386 million. Herbalife is another MLM that sells meal replacements and appetite suppressants, via health coaches. Their weight loss product sales in North America only declined by an
A Tale of Two MLM Competitors Read More »
March 12, 2026 The FDA is finally cracking down on telehealth companies marketing compounded weight loss drugs, warning them not to imply their products are FDA-approved or that they manufacture the medications. Roughly 30% of the more than 70 telehealth companies warned in the past six months rely on just four nationwide “white-label” medical groups
FDA Cracks Down on Telehealth Companies Read More »
Jan. 6, 2026 Novo Nordisk launched the pill version of its popular obesity medication Wegovy on Monday Jan. 5. The firm aimed to capture patients with a cash-pay discount — $149 a month for the lowest starting doses of the medication through April 15. It’s also trying to onboard new patients through a growing number
Telehealth Companies Offer Novo’s Wegovy pill Read More »
Nov. 17, 2025 Due to increased competition in the weight loss market and intense pressure from President Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients. This is is the latest step in the firm’s efforts to provide discounts to Americans willing to buy
Novo Nordisk Lowers Weight Loss Drug Prices Read More »
Nov. 6, 2025 CNBC reported today that President Donald Trump announced deals with Eli Lilly and Novo Nordisk and Eli Lilly toslash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatment. The agreements will cut prices of so-called GLP-1 drugs for
Trump Cuts Deal To Lower Weight Loss Drug Prices Read More »
Sept. 23, 2025 Soon, there may be a promising alternative for the needle-averse, as results of a recent Phase 3 trial confirmed that a daily 25-milligram semaglutide pill can trigger significant weight loss. “We all knew this was coming, and we all feel that it could potentially be a game changer in terms of adopting
Weight Loss Pills Are On The Horizon Read More »